Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
22 hedge funds and large institutions have $3.38M invested in Aridis Pharmaceuticals Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more capital invested
Capital invested by funds: $2.96M → $3.38M (+$423K)
10% more funds holding
Funds holding: 20 → 22 (+2)
4.64% more ownership
Funds ownership: 9.04% → 13.68% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$1.05M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$130K |
| 3 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
+$94.6K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$51.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$92K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$83.7K |
| 3 |
VF
Virtu Financial
New York
|
-$28K |
| 4 |
BlackRock
New York
|
-$14K |
| 5 |
Citigroup
New York
|
-$2K |
ARDS Hedge Fund Activity: Q1 2022 in Review
22 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2022, worth a combined $3.38M — up 14% from $2.96M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ARDS positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Commonwealth Equity Services, adding an estimated $1.05M. The largest seller was Jane Street, exiting entirely with an estimated $92K sold.
- 22 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $3.38M of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2022, up 14% quarter-over-quarter.
- 5 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2022 was Commonwealth Equity Services, an estimated $1.05M added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2022 was Jane Street, an estimated $92K sold.
Based on aggregated 13F filings for Q1 2022.